Aspira Pathlab & Diagnostics Ltd - 540788 - Results- Unaudited Financials Results June 30, 2021
Results- Unaudited Financials Results June 30, 202114-08-2021
14-08-2021
Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Outcome for Outcome Of Board Meeting Held On August 14, 2021
Outcome of Board Meeting held on August 14, 202114-08-2021
Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Intimation For Consideration And Approval Of Unaudited Financial Results For Quarter Ended June 30, 2021
Board Meeting Intimation for consideration and approval of Unaudited Financial Results for quarter ended June 30, 202108-08-2021
Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Intimation For Consideration And Approval Of Unaudited Financial Results For Quarter Ended June 30, 2021
Board Meeting Intimation for consideration and approval of Unaudited Financial Results for quarter ended June 30, 202108-08-2021
Aspira Pathlab & Diagnostics Ltd - 540788 - Shareholding for the Period Ended June 30, 2021
Aspira Pathlab & Diagnostics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here13-07-2021
Aspira Pathlab & Diagnostics Ltd - 540788 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Dr Pankaj ShahDesignation :- Managing Director / Whole Time Director10-07-2021
Aspira Pathlab & Diagnostics Ltd - 540788 - Updates Regarding Extension Of Scope Of NABL Accreditation
Pursuant to Regulation 30 and Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, information regarding extension of scope of NABL accreditation.10-07-2021
Aspira Pathlab & Diagnostics Ltd - 540788 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby submit a copy of certificate received from Link Intime (India) Private Limited, Registrar and Share Transfer Agent of the Company, certifying that for the quarter ended June 30, 2021.09-07-2021
Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligation & Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2021.
Pursuant to Regulation 23(9) of Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby submit the disclosure on Related Party Transactions, on standalone basis, drawn in accordance with applicable accounting standards for the half-year ended March 31, 2021.02-07-2021
Aspira Pathlab & Diagnostics Ltd - 540788 - Closure of Trading Window
The financial results of the Company for the quarter ending June 30, 2021 will be declared in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. With reference to the above captioned matter, we would like to inform you that pursuant to the Securities & Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of Conduct for Prevention of Insider Trading ('Code'), the trading window for dealing in securities of the Company will remain closed from July 1, 2021 till 48 Hours after the said Financial Results are communicated to Stock Exchange.30-06-2021